Volume 7, Issue 1 supplement | Drugs - Real World Outcomes

Search all Drugs - Real World Outcomes articles

Volume 7, Issue 1 supplement

June 2020

Real World Evidence for Oritavancin Use in Gram-Positive Infections

Issue Editors:

Matteo Bassetti,
Teena Chopra

9 articles in this issue

Real-World Evidence for Oritavancin Use in Gram-Positive Infections

Announcement Open access 01 July 2020 Pages: 1 - 1
Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
Mark Redell
Commentary Open access 25 June 2020 Pages: 2 - 5
The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies
Sandy Estrada
Thomas P. Lodise
Dino Delaportas
Original Research Article Open access 25 June 2020 Pages: 6 - 12
Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience
Lauren E. Brownell
Meagan L. Adamsick
Lucas T Schulz
Original Research Article Open access 26 June 2020 Pages: 13 - 19
Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
Brittany Helton
Ashley MacWhinnie
Steven L. Allison
Original Research Article Open access 25 June 2020 Pages: 20 - 29
Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway
Cristen Whittaker
Thomas P. Lodise
Joseph Reilly
Original Research Article Open access 25 June 2020 Pages: 30 - 35
A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
Warren E. Rose
Paul R. Hutson
Original Research Article Open access 25 June 2020 Pages: 36 - 40
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Nicholas W. Van Hise
Vishnu Chundi
Russell M. Petrak
Original Research Article Open access 25 June 2020 Pages: 41 - 45
Real-World Use of Oritavancin for the Treatment of Osteomyelitis
Patrick J. Scoble
Joseph Reilly
Glenn S. Tillotson
Review Article Open access 25 June 2020 Pages: 46 - 54